Tonix Pharmaceuticals stock halted ahead of FDA approval news
Mirum Pharmaceuticals (NASDAQ:MIRM) Chief Executive Officer Christopher Peetz sold 40,000 shares of common stock on August 11, 2025, at a price of $62.0, totaling $2.48 million. The transaction was executed under a Rule 10b5-1 trading plan adopted on November 22, 2024. The sale comes as MIRM trades near its 52-week high of $67.45, having gained over 21% in the past week alone. According to InvestingPro analysis, the $3.25B market cap company currently trades above its Fair Value.
On the same day, Peetz exercised options to acquire 40,000 shares of Mirum Pharmaceuticals common stock at an exercise price of $2.936, for a total value of $117440. Analysts maintain a Strong Buy consensus on the stock, with price targets ranging from $53 to $89.
Following these transactions, Peetz directly owns 138,641 shares of Mirum Pharmaceuticals. Additionally, he indirectly owns 208,570 shares through The Peetz Family Trust. He also owns 158,487 derivative securities in the form of employee stock options. Get deeper insights into MIRM’s valuation metrics and 15+ additional ProTips with a subscription to InvestingPro, including comprehensive analysis in our Pro Research Report.
In other recent news, Mirum Pharmaceuticals reported strong second-quarter 2025 financial results, with total revenues reaching $127.8 million, a 64% increase from the same period in 2024. The company’s earnings per share (EPS) were reported at -$0.12, beating the forecasted -$0.33, and revenue exceeded expectations by a 19.02% surprise. Following this financial performance, Mirum raised its 2025 guidance to $490 million to $510 million, indicating a 48% year-over-year growth at the midpoint. Analyst firms have responded positively, with H.C. Wainwright raising its price target for Mirum Pharmaceuticals to $80 while maintaining a Buy rating. JMP Securities also increased its price target to $81, citing strong quarterly results and maintaining a Market Outperform rating. Stifel resumed coverage of Mirum with a Buy rating and set a price target of $89, highlighting the company’s cash-flow positive business and growth opportunities. These developments reflect a positive outlook for Mirum Pharmaceuticals, bolstered by its recent financial performance and analyst support.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.